The Mentor vs The Apprentice
No one knows how to dig out jewels and reposition a business via accretive, bolt-on M&A like Colin Day who led strategic repositioning at Reckitt Benckiser (“RB”) as a hands-on CFO far more than most appreciate. Moreover, a high conviction investor could have accrued gains as large as 1000% in RB during Colin’s tenure – under the aegis of Bart Becht. Today, Colin is the CEO of Essentra plc (fka Filtrona) and serves as a reminder of the dangers of subconsciously dismissing underlings, namely strategic CFOs.
 Aided by leveraging equity options
The Dream Team
In September 2000, Colin Day joined RB, a consumer products conglomerate, and together with Bart Becht racked up an enviable track record of capital allocation and a rousing share price appreciation.
 Includes the likes of Durex condoms, cleaning agensts Harpix & Dettol along with various OTC drugs
 During Colin’s intial month shares traded at low ~800p to £34.39
#portfolio #hedgefunds #publicmarkets